Policy Applies to
Drugs Addressed in this Policy
FDA-Approved Indication(s)
Seasonal Affective Disorder (SAD, ICD-9 296.99, ICD-10 F34.8): Wellbutrin XL and Aplenzin Background Bupropion is an oral antidepressant agent available in immediate-release, sustained-release and extended release dosage forms; please see above for FDA approved diagnosis information. Bupropion is also available under the proprietary name Zyban® which is an oral sustained-release formulation indicated as an aid to nicotine cessation therapy solely. Zyban® does not carry the labeled FDA approved indication for depression or SAD. Many groups do not include smoking cessation therapy as part of their prescription drug benefit. To prevent the use of bupropion containing products for nicotine cessation therapy when there is no coverage under the prescription drug benefit, groups may choose to prior authorize any bupropion containing product to ensure that it is being used for non-nicotine cessation purposes. Approval Criteria For groups that exclude coverage for nicotine cessation therapy, bupropion products may be covered if all of the following criteria are met:
Duration of Authorization
References
Pharmacy policies do not constitute medical advice, nor are they intended to govern physicians' prescribing or the practice of medicine. They are intended to reflect Highmark's coverage and reimbursement guidelines. Coverage may vary for individual members, based on the terms of the benefit contract. Highmark retains the right to review and update its pharmacy policy at its sole discretion. These guidelines are the proprietary information of Highmark. Any sale, copying or dissemination of the pharmacy policies is prohibited; however, limited copying of pharmacy policies is permitted for individual use. |